|
p>
This FOA encourages research activities in the broad areas of etiology and etiologic mechanism(s) of liver cancer, include, but are not limited to: (a) identification of viral and host factors in initiation of HCC, (b) examination of the development of HCC in the sequelae of HIV infection(c) development of animal models and in vitro virus cultivation methods; (d) development of prevention and control strategies, including chemoprevention; (e), validation of markers; (f) preclinical or clinical trials of promising agents; and (g) imaging studies for diagnosis and intervention.
Research topics include research on the treatment and diagnosis of HCC, including
Conduct of therapeutic clinical trials designed to evaluate novel anticancer agents with distinctive molecular targets, as well as therapeutic combinations of novel agents;
Conduct of clinical translational research on promising biomarkers for determining prognosis and/or predicting response(s) to therapy;
Development of functional imaging techniques that can reliably distinguish HCC from benign hepatic lesions;
Conduct of clinical trials designed to evaluate the role, efficacy, and safety of image-guided local therapies, such as radio-frequency thermal ablation (RFA), particularly in relation to use of liver transplantation for patients with small HCC;
Test of the utility of imaging modalities to evaluate pharmacokinetics and pharmacodynamics of targeted therapies;
Evaluation of the use of imaging as a surrogate marker or endpoint for drug activity in therapeutic clinical trials; and
Development of novel imaging approaches that can be used as diagnostic tools for early detection of HCC.
URL: http://grants.nih.gov/grants/guide/pa-files/PA-08-243.html |
